Daiichi Sankyo Co Ltd WCLC 2025 Briefing  Transcript - Thomson StreetEvents

Daiichi Sankyo Co Ltd WCLC 2025 Briefing Transcript

Daiichi Sankyo Co Ltd WCLC 2025 Briefing  Transcript - Thomson StreetEvents
Daiichi Sankyo Co Ltd WCLC 2025 Briefing Transcript
Published Sep 18, 2025
11 pages (6572 words) — Published Sep 18, 2025
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of 4568.T conference call or presentation 18-Sep-25 10:59am GMT

  
Brief Excerpt:

...Yes. Ken, thank you very much. Thank you for the introduction. So what I'm going to be doing here is to give you an overview of small cell lung cancer as a disease. Next slide, please. First, this is what we call a lung cancer disease map. I think you have seen this from us before. This is a representation of all of lung cancer, small cell lung cancer as well as non-small cell lung cancer in various lines of therapy. And for today, we're going to focus on the small cell lung cancer, which is the yellow boxes in lower rate -- you'll see that it is a smaller part of the lung cancer field. But because there are so many people with lung cancer, it still represents a sizable numbers of patients. So next slide. So first about the disease itself is mostly more common in men or older patients. All the cases are basically attributed to smoking. You'll see here on the right-hand side that it is a very bad disease. Lung cancer in general is bad, but when we compare small cell lung cancer versus non-small...

  
Report Type:

Transcript

Source:
Company:
Ticker
4568.T
Time
10:59am GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Hidemaru Yamaguchi - Citi Infrastructure Investments LLC - Analyst : This is Yamaguchi from Citi. I have two questions. First question is regarding complete response of I-DXd at the third line, which is very interesting and -- but we don't see anything in the second line. And also regarding to this one, is there any background of why you get your BTD for this asset. So is it related to this share rate at the sideline. That's the first question.


Question: Hidemaru Yamaguchi - Citi Infrastructure Investments LLC - Analyst : Yes.


Question: Hidemaru Yamaguchi - Citi Infrastructure Investments LLC - Analyst : And quickly on the second question on the -- it's too early to say, but everybody is trying to compare what's on the market and what (inaudible) of the competitive landscape. And (inaudible), did show some interesting data already and its on the market. Just looking at PFS or ORR or maybe OS, this seems to the same range rather than different range. So can you talk about what you are trying to differentiate in the future as a plan.


Question: Hidemaru Yamaguchi - Citi Infrastructure Investments LLC - Analyst : Yes. Just one question. So regarding BTD. I understand BTD is one of the most, I would say, powerful sort of variation from the FDA so far. But given there are so many trials going on and the Phase 3 is already going on, I understand probably the success may be higher, but can you give me some example where you can, I would say, extend the shorten the timeline of approval where you can find out those time value of BTD of your whole I-DXd program.

Table Of Contents

Daiichi Sankyo Co Ltd Science and Technology Day Transcript – 2025-12-15 – US$ 54.00 – Edited Transcript of 4568.T corporate analyst meeting</ 15-Dec-25 10:30pm GMT

Daiichi Sankyo Co Ltd Q2 2026 Earnings Presentation Transcript – 2025-10-31 – US$ 54.00 – Edited Transcript of 4568.T earnings conference call or presentation 31-Oct-25 6:30am GMT

Daiichi Sankyo Co Ltd ESMO 2025 Highlights Transcript – 2025-10-21 – US$ 54.00 – Edited Transcript of 4568.T conference call or presentation 21-Oct-25 7:00am GMT

Daiichi Sankyo Co Ltd Q1 2026 Earnings Presentation Transcript – 2025-07-31 – US$ 54.00 – Edited Transcript of 4568.T earnings conference call or presentation 31-Jul-25 4:00am GMT

Daiichi Sankyo Co Ltd ASCO 2025 Briefing Transcript – 2025-06-02 – US$ 54.00 – Edited Transcript of 4568.T conference call or presentation 2-Jun-25 11:00pm GMT

Full Year 2025 Daiichi Sankyo Co Ltd Earnings Presentation Transcript – 2025-04-25 – US$ 54.00 – Edited Transcript of 4568.T earnings conference call or presentation 25-Apr-25 6:00am GMT

Daiichi Sankyo Co Ltd Oncology Business Briefing Transcript – 2025-02-25 – US$ 54.00 – Edited Transcript of 4568.T conference call or presentation 25-Feb-25 10:30pm GMT

Daiichi Sankyo Co Ltd Q3 2025 Earnings Presentation Transcript – 2025-01-31 – US$ 54.00 – Edited Transcript of 4568.T earnings conference call or presentation 31-Jan-25 6:00am GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Daiichi Sankyo Co Ltd WCLC 2025 Briefing Transcript" Sep 18, 2025. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Daiichi-Sankyo-Co-Ltd-WCLC-2025-Briefing-T16506625>
  
APA:
Thomson StreetEvents. (2025). Daiichi Sankyo Co Ltd WCLC 2025 Briefing Transcript Sep 18, 2025. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Daiichi-Sankyo-Co-Ltd-WCLC-2025-Briefing-T16506625>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.